Multidisciplinary Management of Gastric Cancer

Surgical Oncology Clinics of North America

Volumn 22, Issue 2, 2013, Pages 247-264

  Misleh, Jamal G ^a   Santoro, Peter ^a   Strasser, Jonathon F ^a   Bennett, Joseph J ^a  

^a HELEN F GRAHAM CANCER CENTER   (United States)

Author keywords

Adjuvant; Chemotherapy; D2 lymphadenectomy; Gastric cancer; Multidisciplinary

Indexed keywords

ANTHRACYCLINE; BIOLOGICAL PRODUCT; CAPECITABINE; CISPLATIN; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; FLUOROPYRIMIDINE DERIVATIVE; FLUOROURACIL; FOLINIC ACID; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; IRINOTECAN; METHOTREXATE; MITOMYCIN; OXALIPLATIN; PACLITAXEL; TAXANE DERIVATIVE; TEGAFUR; TRASTUZUMAB; URACIL;

ADJUVANT CHEMORADIOTHERAPY; ANTINEOPLASTIC ACTIVITY; CANCER PALLIATIVE THERAPY; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CANCER THERAPY; DIARRHEA; DRUG METABOLISM; DRUG TREATMENT FAILURE; ENDOSCOPIC MUCOSAL RESECTION; GASTRECTOMY; HAND FOOT AND MOUTH DISEASE; HEART EJECTION FRACTION; HUMAN; KIDNEY DYSFUNCTION; LOWER ESOPHAGUS SPHINCTER CANCER; LYMPH NODE DISSECTION; MARUYAMA INDEX; METASTASIS; MINIMALLY INVASIVE PROCEDURE; MULTIDISCIPLINARY MANAGEMENT; MULTIPLE CYCLE TREATMENT; NEUROPATHY; NEUTROPENIA; POSTOPERATIVE COMPLICATION; QUALITY OF LIFE; RATING SCALE; REVIEW; SIDE EFFECT; SPLENECTOMY; STOMACH ADENOCARCINOMA; STOMACH CANCER; SURGICAL MORTALITY; THROMBOEMBOLISM; UNSPECIFIED SIDE EFFECT;

CLINICAL TRIALS AS TOPIC; COMBINED MODALITY THERAPY; HUMANS; PATIENT CARE TEAM; PRACTICE GUIDELINES AS TOPIC; STOMACH NEOPLASMS;

EID: 84875527653     PISSN: 10553207     EISSN: 15585042     Source Type: Journal    
DOI: 10.1016/j.soc.2012.12.013     Document Type: Review

References (76)

1. SEER Cancer Statistics. Available at: . Accessed January 22, 2013. http://www.seer.cancer.gov/statistics/.
2. Wijnhoven B.P., Siersema P.D., Hop W.C., et al. Adenocarcinomas of the distal esophagus and gastric cardia are one clinical entity. Rotterdam Esophageal Tumor Group. Br J Surg 1999, 86:529.
3. Klein Kranenbarg E., Hermans J., van Krieken J.H., et al. Evaluation of the 5th edition of the TNM classification for gastric cancer: improved prognostic value. Br J Cancer 2001, 84:64.
4. Rudiger Siewert J., Feith M., Werner M., et al. Adenocarcinoma of the esophagogastric junction: results of the surgical therapy based on anatomical/topographic classification in 1002 consecutive patients. Ann Surg 2000, 232:353.
5. Edge S.B., Compton C.C. American Joint Committee on Cancer staging manual 2010, Springer, New York. 7th edition.
6. McNeer G., Bowden L., Booner R.J., et al. Elective total gastrectomy for cancer of the stomach: end results. Ann Surg 1974, 180(2):252-256.
7. Gouzi J.L., Huguier M., Fogniez P.L., et al. Total versus subtotal gastrectomy for adenocarcinoma of the antrum. A French prospective controlled study. Ann Surg 1989, 209:162-166.
8. Bozzetti F., Marubini E., Bonfanti G., et al. Subtotal versus total gastrectomy for gastric cancer: five-year survival rates in a multicenter randomized Italian trial. Italian Gastrointestinal Tumor Study Group. Ann Surg 1999, 230(2):170-178.
9. Japanese Gastric Cancer Association Japanese classification of gastric carcinoma: 3rd English edition. Gastric Cancer 2011, 14:101-112.
10. Bickenbach K., Strong V.E. Comparisons of gastric treatments: east vs. west. J Gastric Cancer 2012, 12(2):55-62.
11. Cuschieri A., Fayers P., Fielding J., et al. Postoperative morbidity and mortality after D1 and D2 resections for gastric cancer: preliminary results of the MRC randomized surgical trial. The Surgical Cooperative Group. Lancet 1996, 347(9007):995-999.
12. Cuschieri A., Weeden S., Fielding J., et al. Patient survival after D1 and D2 resections for gastric cancer: long-term results of the MRC randomized surgical trial. The Surgical Cooperative Group. Br J Cancer 1999, 79(9-10):1522-1530.
13. Bonenkamp J.J., Songun I., Hermans J., et al. Randomized comparison of morbidity after D1 and D2 dissection for gastric cancer in 996 Dutch patients. Lancet 1995, 345(8952):745-748.
14. Bonenkamp J.J., Hermans J., Sasako M., Dutch Gastric Cancer Group, et al. Extended lymph-node dissection for gastric cancer. N Engl J Med 1999, 340(12):908-914.
15. Hartgrink H.H., Van De Velde C.J., Putter H., et al. Extended Lymph node dissection for gastric cancer: who may benefit? Final results of the Randomized Dutch Gastric Cancer Group Trial. J Clin Oncol 2004, 22:2069-2077.
16. Songun I., Putter H., Kranenbarg E.M., et al. Surgical treatment of gastric cancer: 15 year follow-up results of the randomized nationwide Dutch D1D2 trial. Lancet Oncol 2010, 11(5):439-449.
17. Siewert J.R., Bottcher K., Stein J.H., et al. Relevant prognostic factors in gastric cancer: ten-year results of the German Gastric Cancer Study. Ann Surg 1998, 228:449-461.
18. Kampschoer G.H., Maruyama K., van de Velde C.J., et al. Computer analysis in making preoperative decisions: a rational approach to lymph node dissection in gastric cancer patients. Br J Surg 1989, 76(9):905-908.
19. Bollschweiler E., Boettcher K., Hoelscher A.H., et al. Preoperative assessment of lymph node metastases in patients with gastric cancer: evaluation of the Maruyama computer program. Br J Surg 1992, 79(2):156-160.
20. Hundahl S., Peeters K., Kranenbarg E.K., et al. Improved regional control and survival with " low Maruyama index" surgery in gastric cancer: autopsy findings from the Dutch D1-D2 Trial. Gastric Cancer 2007, 10:84-86.
21. Guadagni S., de Manzoni G., Catarci M., et al. Evaluation of the Maruyama computer program accuracy for preoperative estimation of lymph node metastases from gastric cancer. World J Surg 2000, 24(12):1550-1558.
22. Peeters K., Hundahl S., Kranenbarg E.K., et al. " Low Maruyama index" surgery for gastric cancer: a blinded re-analysis of the Dutch D1-D2 Trial. World J Surg 2005, 29:1576-1584.
23. Burke E.C., Karpek M.S., Conlon K.C., et al. Laparoscopy in the management of gastric adenocarcinoma. Ann Surg 1997, 225:262-267.
24. Muntean V., Mihailov A., Iancu C., et al. Staging laparoscopy in gastric cancer. Accuracy and impact on therapy. J Gastrointestin Liver Dis 2009, 18(2):189-195.
25. Zeng Y.K., Yang Z.L., Peng J.S., et al. Laparoscopy-assisted versus open distal gastrectomy for early gastric cancer: evidence from randomized and nonrandomized clinical trials. Ann Surg 2012, 256(1):39-52.
26. Ono H., Kondo H., Gotoda T., et al. Endoscopic mucosal resection for treatment of early gastric cancer. Gut 2001, 48(2):225-229.
27. Cornelis J.H., van de Velde., Koen C.M.J., et al. The gastric cancer treatment controversy. J Clin Oncol 2003, 21:2234.
28. Cunningham D., Allum W., Stenning S., et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006, 355:11.
29. Boige V., Pignon J., Saint-Aubert B., et al. Final results of a randomized trial comparing preoperative 5-fluorouracil/cisplatin to surgery alone in adenocarcinoma of stomach and lower esophagus (ASLE): FNLCC ACCORD07-FFCD 9703 trial. J Clin Oncol 2007, 25:200. [abstract].
30. Ychou M., Boige V., Pignon J., et al. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: FNCLCC and FFCD multicenter phase III trial. J Clin Oncol 2011, 29:1715.
31. Cascinu S., Labiance R., Barone C., et al. Adjuvant treatment of highrisk, radically resected gastric cancer patients with 5-fluorouracil, leucovorin, cisplatin, and epidoxorubicin in a randomized controlled trial. J Natl Cancer Inst 2007, 99:601.
32. Schuhmacher C., Gretschel S., Lordick F., et al. Neoadjuvant chemotherapy compared with surgery alone for locally advanced cancer of the stomach and cardia: European Organisation for Research and Treatment of Cancer randomized trial 40954. J Clin Oncol 2010, 28:5210.
33. Kobayashi T., Kimura T. Long-term outcome of preoperative chemotherapy with 5'-deoxy-5fluorouridine (5'-DFUR) for gastric cancer. Gan To Kagaku Ryoho 2000, 27:1521.
34. Hallisey M.T., Dunn J.A., Ward L.C., et al. The second British Stomach Cancer Group Trial of adjuvant radiotherapy or chemotherapy in resectable gastric cancer: a five year followup. Lancet 1994, 343:1309.
35. Zhang Z.X., Gu X.Z., Yin W.B., et al. Randomized clinical trial on the combination of preoperative irradiation and surgery in the treatment of adenocarcinoma of gastric cardia (AGC) report on 370 patients. Int J Radiat Oncol Biol Phys 1998, 42:929.
36. Sindelar W., Kinsela T., Chen P., et al. Intraoperative radiotherapy in retroperitoneal sarcomas: final results of a prospective, randomized clinical trial. Arch Surg 1993, 128:402.
37. MacDonald J.S., Smalley S.R., Benedetti J., et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 2001, 345:725.
38. Fuchs C.S., Tepper J.E., Niedzwiecki D., et al. Postoperative adjuvant chemoradiation for gastric or gastroesophageal junction (GEJ) adenocarcinoma using epirubicin, cisplatin, and infusional (CI) 5-FU (ECF) before and after CI 5-FU and radiotherapy (CRT) compared with bolus 5-FU/LV before and after CRT: Intergroup trial CALGB 80101. J Clin Oncol 2011, 29:4003.
39. Lee J., Lim D.H., Kim S., et al. Phase III trial comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer with D2 lymph node dissection: ARTIST trial. J Clin Oncol 2012, 30:268.
40. Higgins G., Amadeo J., Smith D., et al. Efficacy of prolonged intermittent therapy with combined 5-FU and methyl-CCNU following resection for gastric carcinoma, A Veterans Administration Surgical Oncology, Group Report. Cancer 1983, 52:1105-1112.
41. Engstrom P., Lavin P., Douglass H., et al. Postoperative adjuvant 5-fluorouracil plus methyl-CCNU therapy for gastric cancer patients, Eastern Cooperative Oncology Group Study (EST 3275). Cancer 1985, 55:1868-1873.
42. Bonfanti G. Adjuvant treatments following curative resection for gastric cancer. The Italian Gastrointestinal Tumor Study Group. Br J Surg 1988, 75:1100-1104.
43. Allum W., Hallissey M., Ward L., et al. A controlled, prospective, randomized trial of adjuvant chemotherapy or radiotherapy in resectable gastric cancer: interim report. British Stomach Cancer Group. Br J Cancer 1989, 60:739-744.
44. Coombs R., Schein P., Chilvers C., et al. A randomized trial comparing adjuvant fluorouracil, doxorubicin, and mitomycin with no treatment in operable gastric cancer. International Collaborative Cancer Group. J Clin Oncology 1990, 8:1362-1369.
45. Nitti D., Wils J., Dos Santos J., et al. Randomized Phase III trial of adjuvant FAMTX or FEMTX compared with surgery alone in resected gastric cancer. A combined analysis of the EORTC GI Group and the ICCG. Ann Oncol 2006, 2:2629.
46. Nashimoto A., Nakajima T., Furukawa H., Gastric Cancer Surgical Study Group, Japan Clinical Oncology Group, et al. Randomized trial of adjuvant chemotherapy with mitomycin, fluorouracil, and cytosine arabinoside followed by oral fluorouracil in serosa-negative gastric cancer: Japan Clinical Oncology Group 9206-1. J Clin Oncol 2003, 21(12):2282-2287.
47. Earle C.C., Maroun J.A. Ajuvant chemotherapy after curative resection for gastric cancer in non-Asian patients: revisiting a meta-analysis of randomized trials. Eur J Cancer 1999, 35:1059.
48. Mari E., Floriani I., Tinazzi A., et al. Efficacy of adjuvant chemotherapy after curative resection for gastric cancer: a meta-analysis of published randomized trials. A study of the GISCAD. Ann Oncol 2000, 11:837.
49. Sun P., Xiang J., Chen Z. Meta-analysis of adjuvant chemotherapy after radical surgery for advanced gastric cancer. Br J Surg 2009, 96:26.
50. Paoletti X., Oba K., Burzykowski T., GASTRIC Group, et al. Benefit of adjuvant chemotherapy for resectable gastric cancer: a meta-analysis. JAMA 2010, 303:1729.
51. Sasako M., Sakuramoto S., Katai H., et al. Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S1 versus surgery alone in stage II or III gastric cancer. J Clin Oncol 2011, 29:4387.
52. Bang Y.J., Kim Y.W., Yang H.K., et al. Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomized controlled trial. Lancet 2012, 379:315.
53. Glimelius B., Ekstrom K., Hoffman K., et al. Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. Ann Oncol 1997, 8:163.
54. Wagner A.D., Grothe W., Haerting J., et al. Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. J Clin Oncol 2006, 24:2903.
55. Hong Y.S., Song S.Y., Lee S.I., et al. A phase II trial of capecitabine in previously untreated patients with advanced and/or metastatic gastric cancer. Ann Oncol 2004, 15:1344.
56. Koizumi W., Saigenji K., Ujiie S., et al. A pilot phase II study of capecitabine in advanced or recurrent gastric cancer. Oncology 2003, 64:232.
57. van Groeningen C.J., Peters G.J., Schornagel J.H., et al. Phase I clinical and pharmacokinetic study of oral S-1 in patients with advanced solid tumors. J Clin Oncol 2000, 18:2772.
58. Boku N., Yamamoto S., Fukuda H., et al. Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomized phase 3 study. Lancet Oncol 2009, 10:1063.
59. Lee J.L., Kang Y.K., Kang H.J., et al. A randomized multicenter phase II trial of capecitabine vs. S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer. Br J Cancer 2008, 99:584.
60. Jeung H.C., Rha S.Y., Shin S.J., et al. A phase II study of S-1 monotherapy administered for 2 weeks of a 3-week cycle in advanced gastric cancer patients with poor performance status. Br J Cancer 2007, 97:458.
61. Ajani J.A., Rodriguez W., Bodoky G., et al. Multicenter phase III comparison of cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: the FLAGS trial. J Clin Oncol 2010, 28:1547.
62. Kang Y.K., Kang W.K., Shin D.B., et al. Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomized phase III noninferiority trial. Ann Oncol 2009, 20:666.
63. Ohtsu A., Shimada Y., Shirao K., et al. Randomized phase III trial of fluorouracil alone versus fluorouracil plus cisplatin versus uracil and tegafur plus mitomycin in patients with unresectable, advanced gastric cancer: JCOG9205. J Clin Oncol 2003, 21:54.
64. Koizumi W., Narahara H., Hara T., et al. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS) trial: a phase III trial. Lancet Oncol 2008, 9:215.
65. Cullinan S.A., Moertel C.G., Flemming T.R., et al. A comparison of three chemotherapeutic regimens in the treatment of advanced pancreatic and gastric carcinoma. Fluorouracil vs. fluorouracil and doxorubicin vs. fluorouracil, doxorubicin, and mitomycin. JAMA 1985, 253:2061.
66. Findlay M., Cunningham D., Norman A., et al. A phase II study in advanced gastro-esophageal cancer using epirubicin and cisplatin in combination with continuous infusion 5-fluorouracil (ECF). Ann Oncol 1994, 5:609.
67. Webb A., Cunningham D., Scarffe J.H., et al. Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. J Clin Oncol 1997, 15:261.
68. Ross P., Nicolson M., Cunningham D., et al. Prospective randomized trial comparing mitomycin, cisplatin, and protracted venous-infusion fluorouracil with epirubicin, cisplatin and PVI 5-FU in advanced esophagogastric cancer. J Clin Oncol 2002, 20:1996.
69. Wagner A.D., Unverzagt S., Grothe W., et al. Chemotherapy for advanced gastric cancer. Cochrane Database Syst Rev 2010, (3). CD004064.
70. Enzinger P.C., Burtness B., Hollis D., et al. CALGB 80403/ECOG 1206: a randomized phase II trial of three standard chemotherapy regimens (SCF, IC, FOLFOX) plus cetuximab in metastatic esophageal and GE junction cancer. J Clin Oncol 2010, 28:302. [abstract 4006].
71. Cunningham D., Starling N., Rao S., et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 2008, 358:36.
72. Al-Batran S.E., Hartmann J.T., Probst S., et al. Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie. J Clin Oncol 2008, 26:1435.
73. van Cutsem E., Moiseyenko V.M., Tjulandin S., et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol 2006, 24:4991.
74. Roth A.D., Fazio N., Stupp R., et al. Docetaxel, cisplatin, and fluorouracil; docetaxel and cisplatin; and epirubicin, cisplaitn, and fluorouracil as systemic treatment for advanced gastric carcinoma: a randomized phase II trial of the Swiss Group for Clinical Cancer Research. J Clin Oncol 2007, 25:3217.
75. Takehana T., Kunitomo K., Kono K., et al. Status of c-erbB-2 in gastric adenocarcinoma: a comparative study of immunohistochemistry, fluorescence in situ hybridization and enzyme-linked immunosorbent assay. Int J Cancer 2002, 98:833.
76. Bang Y.J., Van Cutsem E., Feyereislova A., et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-esophageal junction cancer (ToGA): a phase 3, open-label, randomized controlled trial. Lancet 2010, 376:687.